The Food and Drug Administration has approved Hibsago (bepirovirsen), a first-of-its-kind treatment designed to help some adults with chronic hepatitis B keep the virus under control after stopping all medication. In clinical trials, 19% of patients who received the drug still had the virus under control 24 weeks after ending all hepatitis B treatment, compared with none who received a placebo, according to the FDA's Oct. 20 announcement.
That result, often called a functional cure, means the virus's DNA and a key viral protein, hepatitis B surface antigen, can no longer be detected in the blood after treatment stops. It does not mean the virus is gone from the body.